Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company’s in vivo CAR-M collaboration with Moderna, and research programs including fibrosis Cash and cash equivalents of…